ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...
The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results